{
    "xml": "<topic id=\"PHP5571\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/topotecan\" basename=\"topotecan\" title=\"TOPOTECAN\">\n<title>TOPOTECAN</title>\n<body>\n<data name=\"vtmid\">108779005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_215732037\" title=\"Topoisomerase I inhibitors\">Topoisomerase I inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP51933\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/topotecan\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Topotecan inhibits topoisomerase I, an enzyme involved in DNA replication.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51903\" outputclass=\"indicationsAndDose\" rev=\"1.17\" parent=\"/drugs/topotecan\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic ovarian cancer when first-line or subsequent treatment has failed</p>\n<p outputclass=\"therapeuticIndication\">Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease (in combination with cisplatin)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51948\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/topotecan\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51773\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/topotecan\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal effects</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">myelosuppression (dose-limiting)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51968\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/topotecan\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51851\" outputclass=\"pregnancy\" parent=\"/drugs/topotecan\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenicity and fetal loss in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52020\" outputclass=\"breastFeeding\" parent=\"/drugs/topotecan\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51908\" outputclass=\"hepaticImpairment\" parent=\"/drugs/topotecan\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51819\" outputclass=\"renalImpairment\" parent=\"/drugs/topotecan\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid infusion if creatinine clearance less than 20&#8239;mL/minute.</p>\n<p>Avoid oral route if creatinine clearance less than 60&#8239;mL/ minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51621\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/topotecan\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA91</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p>\r\n<p>Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy or in those allergic to platinum compounds <i>and</i> for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA183</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) </p>\r\n<p>Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA183\">www.nice.org.uk/TA183</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA184</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)</p>\r\n<p>Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if re-treatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA184\">www.nice.org.uk/TA184</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (November 2007) that topotecan (<i>Hycamtin</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use in combination with cisplatin for treatment of recurrent carcinoma of the cervix after radiotherapy and for stage IVB disease; it is restricted to patients who have not previously received cisplatin treatment.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2009) that use of topotecan capsules within NHS Scotland is restricted to patients in whom standard intravenous chemotherapy is inappropriate and who would otherwise receive best supportive care.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5571-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/topotecan\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75493\" title=\"Capsule\" namespace=\"/drugs/topotecan/capsule\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75499\" title=\"Solution for infusion\" namespace=\"/drugs/topotecan/solution-for-infusion\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75481\" title=\"Powder for solution for infusion\" namespace=\"/drugs/topotecan/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75493\" namespace=\"/drugs/topotecan/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75499\" namespace=\"/drugs/topotecan/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75481\" namespace=\"/drugs/topotecan/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5571",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/topotecan",
    "basename": "topotecan",
    "title": "TOPOTECAN",
    "vtmid": "108779005",
    "drugClassification": [
        "Topoisomerase I inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Topotecan inhibits topoisomerase I, an enzyme involved in DNA replication.",
                "html": "<p>Topotecan inhibits topoisomerase I, an enzyme involved in DNA replication.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Metastatic ovarian cancer when first-line or subsequent treatment has failed",
                        "html": "Metastatic ovarian cancer when first-line or subsequent treatment has failed"
                    },
                    {
                        "textContent": "Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease (in combination with cisplatin)",
                        "html": "Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease (in combination with cisplatin)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate",
                        "html": "Relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or mouth"
                    ],
                    "textContent": "By intravenous infusion or by mouth",
                    "html": "By intravenous infusion or by mouth"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal effects",
                        "html": "gastro-intestinal effects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression (dose-limiting)",
                        "html": "myelosuppression (dose-limiting)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenicity and fetal loss in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenicity and fetal loss in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid infusion if creatinine clearance less than 20 mL/minute.\n\nAvoid oral route if creatinine clearance less than 60 mL/ minute.",
                "html": "<p>Avoid infusion if creatinine clearance less than 20&#8239;mL/minute.</p><p>Avoid oral route if creatinine clearance less than 60&#8239;mL/ minute.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA91",
                        "label": "www.nice.org.uk/TA91"
                    }
                ],
                "fundingIdentifier": "NICE TA91",
                "textContent": "Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy or in those allergic to platinum compounds and for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate.\n\nwww.nice.org.uk/TA91",
                "html": "<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p> <p>Topotecan alone is an option only for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy or in those allergic to platinum compounds <i>and</i> for whom paclitaxel alone or pegylated liposomal doxorubicin are inappropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA183",
                        "label": "www.nice.org.uk/TA183"
                    }
                ],
                "fundingIdentifier": "NICE TA183",
                "textContent": "Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.\n\nwww.nice.org.uk/TA183",
                "html": "<p outputclass=\"title\">Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) </p> <p>Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA183\">www.nice.org.uk/TA183</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA184",
                        "label": "www.nice.org.uk/TA184"
                    }
                ],
                "fundingIdentifier": "NICE TA184",
                "textContent": "Topotecan for the treatment of relapsed small-cell lung cancer (November 2009) Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if re-treatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.\n\nwww.nice.org.uk/TA184",
                "html": "<p outputclass=\"title\">Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)</p> <p>Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if re-treatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated. Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA184\">www.nice.org.uk/TA184</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75493",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75499",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75481",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75493",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75499",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75481",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}